VivoSeq
Hematology

ITP

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

ITP is an early-stage landscape with 0 programs across 3 companies. The most active players are Kyowa Kirin Co., Ltd., Medias Klinikum for Surgical Oncology, Gilead.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalM

Medias Klinikum for Surgical Oncology

0 programs

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Unknown status4 · 33%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 2/3·NCT00440037·44 enrolled
A Study of Zanubrutinib in Patients With ITP
Completed·PPeking University People's Hospital·Phase 2·NCT05279872·20 enrolled
An Investigation of rhTPO With Different Frequencies in the Management of ITP
Completed·SShandong University·Phase 3·NCT02139501·48 enrolled
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·N/A·NCT06071520·50 enrolled
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
Completed·SShandong University·Phase 3·NCT01525836·123 enrolled
Safety Study of AMG 531 in Japanese Subjects With ITP
Completed·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 2·NCT00305435·12 enrolled
Isolated Thoracic Perfusion (ITP-F) for MPM
Completed·MMedias Klinikum for Surgical Oncology·N/A·NCT02467426·23 enrolled
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Terminated·Gilead logoGilead·Phase 1/2·NCT00547066·48 enrolled
H. Pylori Eradication for Moderate ITP
Unknown status·SSeoul National University Hospital·Phase 3·NCT03177629·54 enrolled
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
Unknown status·SShandong University·Phase 3·NCT03443570·200 enrolled
ITP Block: Single or Multiple Injection?
Unknown status·ZZealand University Hospital·Phase 4·NCT05753397·12 enrolled
A Study of Orelabrutinib in Patients With ITP
Unknown status·PPeking University People's Hospital·Phase 1/2·NCT05124028·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)